AcelRx Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
May 10, 2023 at 05:02 pm EDT
Share
AcelRx Pharmaceuticals, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 8.15 million compared to USD 8.67 million a year ago. Basic loss per share was USD 0.75 compared to USD 1.19 a year ago.
Talphera, Inc., formerly AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. LTX-608 is nafamostat formulation for direct intravenous (IV) infusion that shall be investigated and developed as a potential anti-viral for the treatment of COVID, acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), and acute pancreatitis. The Company is also engaged in developing two pre-filled syringes, namely Fedsyra and PFS-02.